I respect your opinion but the issue is that they are clear guidelines, but not hard and fast rules. The FDA approval process is not an exact science. I think JC has oversold something he didn't have in hand and set himself up for this kind of disappointment. GO will be a big enhancement and possibly key to vitiligo penetration with dermatologists, but it's not a necessity for wounds and burns. Approaching it that way would have softened this announcement if it's not truly needed until vitiligo launch Q1 2025. Which was the initial approach to GO.
But hindsight is 20-20 and I still think today's reaction was way overblown. All due respect.
Ann: Form 8-K, page-38
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.08 |
Change
0.000(0.00%) |
Mkt cap ! $216.4M | |||
| Open | High | Low | Value | Volume |
| $3.04 | $3.15 | $3.04 | $227.9K | 73.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3297 | $3.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.08 | 159 | 2 |
View Market Depth
| Last trade - 15.40pm 16/10/2024 (20 minute delay) ? |
| AVH (ASX) Chart |